TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03976375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion of pembrolizumab at 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion of docetaxel at 75 mg/m\^2.
Study: NCT03029403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
Study: NCT04340843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04306367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg given orally.
Study: NCT03029403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
Study: NCT02213003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Description: Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
Study: NCT00813839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily weaning trails
Description: daily SmartCare vs SBT until extubation criteria met

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: daily weaning trails
Description: daily SmartCare vs SBT until extubation criteria met
Study: NCT02875210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laximeter measurement
Study: NCT02865044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wax Ester Marine Oil
Description: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.

Intervention type: OTHER
Group type: OTHER
Intervention: Ethyl Ester Marine Oil
Description: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
Study: NCT04509856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-back educational method
Description: In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
Study: NCT01858883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT04291014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SunRay Light Boxes
Description: SunRay light boxes will be used to administer the light therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SunRay Light Boxes
Description: SunRay light boxes will be used to administer the light therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SunRay Light Boxes
Description: SunRay light boxes will be used to administer the light therapy.
Study: NCT03540485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of placebo orally, for 24 months between 10pm to 11pm
Study: NCT01255787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vortioxetine placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vortioxetine placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vortioxetine placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vortioxetine placebo-matching tablets
Study: NCT03413943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze training
Description: Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze training
Description: Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: gaze training
Description: Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
Study: NCT01866553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 300 mg capsule BID oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2b
Description: 25 - 40 microgram per week for subcutaneous use
Study: NCT03381157

Intervention type: OTHER
Intervention: Observational General Movements Assessments
Description: GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions

Intervention type: OTHER
Intervention: Observational General Movements Assessments
Description: GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
Study: NCT01429038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
Study: NCT03494777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivization based on high adherence
Description: When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivization based on timely clinic visit
Description: When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Annual adherence prize drawing
Description: Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Annual viral suppression-based prize drawing
Description: Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Year 2 booster
Description: Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Year 2 booster
Description: Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
Study: NCT05141825

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton and carbon ion radiotherapy
Description: proton and carbon ion radiotherapy
Study: NCT01148797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study: NCT00542451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Every week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
Study: NCT00688727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: CBT, up to 12 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Routine review by neuropsychiatrist in outpatient clinic
Study: NCT02552615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: body awareness therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stabilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercises
Study: NCT01552473

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Training Program 1
Description: The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training Program 2
Description: The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
Study: NCT01799577

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Two methods will be compare
Study: NCT01165632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo stereotactic craniotomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation
Description: Undergo radiation therapy treatment planning/simulation
Study: NCT03406442

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transpterygoid approaches
Description: All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
Study: NCT03989089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol.
Study: NCT01165632

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo positron emission tomography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorodopa
Description: Given IV
Study: NCT03586622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (LFD)
Description: The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
Study: NCT04214418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: (40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: (40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: (40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: (40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: (600mg) orally twice daily on days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: (600mg) orally twice daily on days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: (600mg) orally twice daily on days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: (600mg) orally twice daily on days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
Study: NCT03586622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3®
Description: VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum\* BL03, B. infantis\* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus\*\* BD08; \*Recently reclassified as B. animalis subsp. lactis \*\* Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
Study: NCT04990648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
Study: NCT01679158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using The IOP system from USGI to place suture anchors
Description: Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using The IOP system from USGI to place suture anchors
Description: Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using The IOP system from USGI to place suture anchors
Description: Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control
Study: NCT03905967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
Study: NCT00465218

Intervention type: PROCEDURE
Intervention: Prophylaxis of Thrombosis after aortic valve replacement
Description: Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5

Intervention type: PROCEDURE
Intervention: Prophylaxis of Thrombosis after aortic valve replacement
Description: Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
Study: NCT04026243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: U/S guided Transmuscular Quadratus Lumborum Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TF block
Description: U/S guided Transversalis Fascia Plane Block
Study: NCT02265679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, low dose, pediatric patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, medium dose, pediatric patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, high dose, pediatric patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, low dose, adult patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, medium dose, adult patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, high dose, adult patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo